<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Infectious%20Diseases/Candidiasis/">
    <link rel="shortcut icon" href="../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Candidiasis - MedNotes</title>
    <link href="../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../js/jquery-3.2.1.min.js"></script>
    <script src="../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Candidiasis", url: "#_top", children: [
              {title: "Summary (2016 IDSA Guidelines)", url: "#summary-2016-idsa-guidelines" },
              {title: "Reference", url: "#reference" },
          ]},
        ];

    </script>
    <script src="../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Capnocytophaga/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Capnocytophaga/" class="btn btn-xs btn-link">
        Introduction
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Babesiosis/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Babesiosis/" class="btn btn-xs btn-link">
        Babesiosis
      </a>
    </div>
    
  </div>

    

    <h1 id="candidiasis">Candidiasis</h1>
<h2 id="summary-2016-idsa-guidelines">Summary (2016 IDSA Guidelines)</h2>
<h3 id="candidemia-in-non-neutropenic-patients">Candidemia in Non-Neutropenic Patients</h3>
<ol>
<li>Initial Therapy<ol>
<li><strong>Echinocandin</strong> <strong>is recommended as initial therapy</strong> (caspofungin 70 mg loading then 50 mg daily; micafungin 100 mg daily; anidulafungin 200 mg then 100 mg daily).<ol>
<li>Testing for echinocandin susceptibility should be considered in patients who have had prior treatment with an echinocandin and among those who have infection with <em>C. glabrata</em> or <em>C. parapsilosis</em></li>
</ol>
</li>
<li><strong>Fluconazole is acceptable alternative</strong> (800 mg loading dose or 12 mg/kg, then 400 mg or 6 mg/kg) daily. For selected patients (not critically ill, low risk of fluconazole resistant Candida)<ol>
<li>Testing for azole susceptibility is recommended for all bloodstream and other clinically relevant <em>Candida</em> isolates.</li>
<li>Voriconazole 400 mg (6 mg/kg) twice daily for 2 doses, then 200 mg (3 mg/kg) twice daily is effective for candidemia, but offers little advantage over fluconazole as initial therapy</li>
</ol>
</li>
<li><strong>Lipid formulation amphotericin B (AmB) (3–5 mg/kg daily) is a reasonable alternative</strong> if there is intolerance, limited availability, or resistance to other antifungal agents</li>
</ol>
</li>
<li>Transitioning<ol>
<li><strong>Transition from echinocandin to fluconazole is recommended</strong> for patients who are clinically stable, have susceptible isolates (e.g. <em>albicans</em>, and repeat negative blood cultures after starting antifungal therapy, within 5-7 days usually.</li>
<li><strong>Transition from AmB to fluconazole is recommended</strong> after 5–7 days among patients who have isolates that are susceptible to fluconazole, who are clinically stable, and in whom repeat cultures on antifungal therapy are negative</li>
<li><strong>For infection due to <em>C. glabrata</em></strong>, transition to higher-dose fluconazole 800 mg (12 mg/kg) daily or voriconazole 200–300 (3–4 mg/kg) twice daily should only be considered among patients with fluconazole-susceptible or voriconazole-susceptible isolate</li>
<li><strong>Voriconazole</strong> is recommended as step-down oral therapy for selected cases of candidemia due to <em>C. krusei</em></li>
</ol>
</li>
<li>Duration<ol>
<li><strong>Follow-up blood cultures should be performed every day or every other day</strong> to establish the time point at which candidemia has been cleared</li>
<li>Recommended duration of therapy for candidemia <strong>without obvious metastatic complications</strong> is for <strong>2 weeks after documented clearance of <em>Candida</em> species from the bloodstream and resolution of symptoms attributable to</strong> candidemia.</li>
</ol>
</li>
<li>Other<ol>
<li>All nonneutropenic patients with candidemia should have a dilated ophthalmological examination, preferably performed by an ophthalmologist, within the first week after diagnosis</li>
</ol>
</li>
</ol>
<h3 id="candidemia-in-neutropenic-patients-differences-only">Candidemia in Neutropenic Patients (Differences only)</h3>
<ol>
<li><strong>Fluconazole</strong>, 400 mg (6 mg/kg) daily, can be used for step-down therapy during persistent neutropenia in clinically stable patients who have susceptible isolates and documented bloodstream clearanc.</li>
<li><strong>Voriconazole</strong>, 400 mg (6 mg/kg) twice daily for 2 doses, then 200–300 mg (3–4 mg/kg) twice daily, can be used in situations in which <strong>additional mold coverage is desired</strong>.</li>
<li>For infections due to <em>C. krusei</em>, an echinocandin, lipid formulation AmB, or voriconazole is recommended</li>
<li>Recommended minimum duration of therapy for candidemia without metastatic complications is 2 weeks after documented clearance of <em>Candida</em> from the bloodstream, provided <strong>neutropenia</strong> and symptoms attributable to candidemia have resolve.</li>
<li>Ophthalmological findings of choroidal and vitreal infection are minimal until recovery from neutropenia; therefore, <strong>dilated fundoscopic examinations should be performed within the first week after recovery from neutropenia</strong></li>
<li>In the neutropenic patient, sources of candidiasis other than a <a href="../../Critical%20Care/Procedures/Central%20Lines/">CVC</a> (eg, gastrointestinal tract) predominate</li>
<li>Granulocyte colony-stimulating factor (G-CSF)–mobilized granulocyte transfusions can be considered in cases of persistent candidemia with anticipated protracted neutropenia</li>
</ol>
<h3 id="chronic-disseminated-hepatosplenic-candidiasis">Chronic Disseminated (Hepatosplenic) Candidiasis</h3>
<h3 id="invasive-candidiasis-in-the-icu">Invasive Candidiasis in the ICU</h3>
<h4 id="empiric-treatment">Empiric Treatment</h4>
<h4 id="prophylaxis">Prophylaxis</h4>
<h3 id="intraabdominal-candidiasis">Intraabdominal Candidiasis</h3>
<ol>
<li>The <strong>choice of antifungal therapy is the same</strong> <strong>as for the treatment of candidemia</strong> or empiric therapy for nonneutropenic patients in the ICU</li>
<li>Treatment of intra-abdominal candidiasis should include source control, with appropriate drainage and/or debridement</li>
</ol>
<h3 id="candidal-intravascular-infections">Candidal Intravascular Infections</h3>
<h3 id="osteoarticular-infections">Osteoarticular Infections</h3>
<h3 id="cns-candidiasis">CNS Candidiasis</h3>
<h3 id="urinary-tract-infections">Urinary Tract Infections</h3>
<h3 id="vulvovaginal-candidiasis">Vulvovaginal Candidiasis</h3>
<h3 id="oropharyngeal-candidiasis">Oropharyngeal Candidiasis</h3>
<ul>
<li><strong>mild disease</strong><ul>
<li>clotrimazole troches, 10 mg 5 times daily or miconazole mucoadhesive buccal 50-mg tablet applied to the mucosal surface over the canine fossa once daily for 7–14 days are recommended</li>
<li>nystatin suspension (100 000 U/mL) 4–6 mL 4 times daily, OR 1–2 nystatin pastilles (200 000 U each) 4 times daily, for 7–14 days</li>
</ul>
</li>
<li><strong>moderate to severe disease</strong><ul>
<li>oral fluconazole, 100–200 mg daily, for 7–14 days</li>
</ul>
</li>
<li><strong>fluconazole refractory disease</strong><ul>
<li>itraconazole solution, 200 mg once daily OR posaconazole suspension, 400 mg twice daily for 3 days then 400 mg daily, for up to 28 day</li>
<li>voriconazole, 200 mg twice daily, OR AmB deoxycholate oral suspension, 100 mg/mL 4 times daily</li>
<li>IV echinocandin or IV AmB</li>
</ul>
</li>
<li>Chronic suppressive therapy is usually unnecessary. If required for patients who have recurrent infection, fluconazole, 100 mg 3 times weekly, is recommended.</li>
<li>For HIV-infected patients, antiretroviral therapy is strongly recommended to reduce the incidence of recurrent infections</li>
<li>For denture-related candidiasis, disinfection of the denture, in addition to antifungal therapy is recommended</li>
</ul>
<h3 id="esophageal-candidiasis">Esophageal Candidiasis</h3>
<ul>
<li><strong>Systemic antifungal therapy is always required</strong>. A diagnostic trial of antifungal therapy is appropriate before performing an endoscopic examination<ul>
<li>Oral fluconazole, 200–400 mg (3–6 mg/kg) daily, for 14–21 days is recommended</li>
<li>For patients who cannot tolerate oral therapy, intravenous fluconazole, 400 mg (6 mg/kg) daily, OR an echinocandin (micafungin, 150 mg daily, caspofungin, 70-mg loading dose, then 50 mg daily, or anidulafungin, 200 mg daily) is recommended</li>
<li>Consider de-escalating to oral therapy with fluconazole 200–400 mg (3–6 mg/kg) daily once the patient is able to tolerate oral intake</li>
</ul>
</li>
<li>For patients who have recurrent esophagitis, chronic suppressive therapy with fluconazole, 100–200 mg 3 times weekly, is recommended</li>
<li>For HIV-infected patients, antiretroviral therapy is strongly recommended to reduce the incidence of recurrent infections</li>
</ul>
<h2 id="reference">Reference</h2>
<ol>
<li>Pappas, Peter G., Carol A. Kauffman, David R. Andes, Cornelius J. Clancy, Kieren A. Marr, Luis Ostrosky-Zeichner, Annette C. Reboli, et al. “Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.” <em>Clinical Infectious Diseases</em> 62, no. 4 (February 15, 2016): e1–50. <a href="https://doi.org/10.1093/cid/civ933">https://doi.org/10.1093/cid/civ933</a>.</li>
</ol>
<hr />
<p><a href="http://medreference.ca:8080/books/infectious-diseases/page/candidiasis/revisions">Revision #1<br />
</a>Created Tue, Apr 12, 2022 3:07 AM by <a href="http://medreference.ca:8080/user/1">Jasper Ho</a><br />
Updated Tue, Apr 12, 2022 3:40 AM by <a href="http://medreference.ca:8080/user/1">Jasper Ho</a></p>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Capnocytophaga/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Capnocytophaga/" class="btn btn-xs btn-link">
        Introduction
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Babesiosis/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Babesiosis/" class="btn btn-xs btn-link">
        Babesiosis
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>